EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)Frank Tacke, Dror Dicker, Paul Horn et al.|Journal of Hepatology|2024Cited by 1.6k
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trialCarel W. le Roux, Aila Rissanen, Arne Astrup et al.|The Lancet|2017Cited by 843
Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE)Massimiliano Caprio, Riccarda Granata, Lorenzo M. Donini et al.|Journal of Endocrinological Investigation|2019Cited by 292
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive SummaryFrank Tacke, Dror Dicker, Paul Horn et al.|Diabetologia|2024Cited by 150
Prognostic value of stem cell markers in esophageal and esophagogastric junction cancer: a meta-analysisElisabetta Trevellin, Roberto Vettor|Journal of Cancer|2020Cited by 9